Brought to you by:
VIVID study on Duo venous stent system now fully enrolled, Vesper Medical announces
Vesper Medical recently announced the completion of enrollment in its pivotal study—VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper Duo venous stent system). VIVID enrolled its 160th patient earlier this month, marking completion of enrollment in the trial.…
‘Meet the Experts’ webinars now available OnDemand
Society for Vascular Surgery (SVS) members now have another chance to “Meet the Experts,” via computer screen and at no charge. Three of the “Meet the Experts” webinars held in spring and summer are now available on SVS OnDemand, part…
VESS: A society primed for young vascular surgeons, trainees and medical students
Welcome to December where the calendar is filled with abstract and registration deadlines to various meetings through the summer of 2022. In this month‘s column, we are highlighting the Vascular and Endovascular Surgery Society (VESS). Formerly known as the Peripheral…
FDA approves two pediatric venous thromboembolism indications for rivaroxaban
The Food and Drug Administration (FDA) has approved two pediatric indications for Xarelto (rivaroxaban): the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of…
CLI at a crossroads: Which direction now?
Vascular surgery once again finds itself at a crossroads, Michael Belkin, MD, chief of the division of vascular and endovascular surgery at Brigham and Women’s Hospital in Boston, told the Western Vascular Society (WVS) annual meeting (Oct. 16–19) in Jackson…
Nominate ‘giver, doer’ for Excellence in Community Service Award
The Society for Vascular Surgery (SVS) is asking members to consider who among the many excellent vascular surgeons they may know in community practice might be worthy of nomination for the 2022 SVS Excellence in Community Service Award. Applications for…
Explaining the No Surprises Act
The vast scope of the No Surprises Act—legislation signed into law in late 2020—may mean some Society for Vascular Surgery (SVS) members are not aware of its provisions. The No Surprises Act is part of the Consolidation Appropriateness Act of…
‘Leveraging multiple teams and cardiovascular specialists’
This quarter’s Leadership Corner features Young Erben, MD, interviewing Charles B. Ross, MD, chief of vascular and endovascular services at Piedmont Heart Institute, Piedmont Hospital, Atlanta, since 2012. I am highlighting the innovative work of Dr. Ross, current medical leader…
TCAR affords greater quality-adjusted life years than carotid endarterectomy, cost-effectiveness model finds
A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR) were higher than those for carotid endarterectomy (CEA), TCAR afforded greater quality-adjusted life years (QALY). The study was published in the December 2021 issue of the…
SVS issues new guidelines covering carotid disease and popliteal aneurysms
The Society for Vascular Surgery (SVS) has released updated clinical practice guidelines for the management of extracranial cerebrovascular disease and popliteal artery aneurysms in a special supplement, “The Care of Patients with Extracranial Cerebrovascular Disease and Popliteal Artery Aneurysms: The…